Search Results

• • 137 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Mechanisms of sulfonylurea's stimulation of insulin secretion in vivo: selective amplification of insulin secretory burst mass

  Authors:Niels K. Porksen, Stephen R. Munn, Jeffery L. Steers, Ole Schmitz, Johannes D. Veldhuis, and Peter C. ButlerFrom:Diabetes (Vol. 45, Issue 12) Peer-Reviewed

  Dec. 19964,012 words Article Although sulfonylurea's enhance insulin secretion, it is unknown whether these hypoglycemic chemicals stimulate insulin secretion through the augmentation of the pulsatile or basal modes of insulin release. Enhanced...

• Sulfonylureas show unfavourable risk profiles

  From:Reactions Weekly (Issue 1283)

  Jan. 9, 2010278 words Brief article 1200LThe risk profiles of sulfonylureas appear unfavourable relative to that of metformin, according to a study investigating the relationship between antihyperglycaemics and the incidences of myocardial infarction,...

• The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild Insulin-Induced hypoglycemia. (Pathophysiology/Complications)

  Authors:Edith W.M.T. Ter Braak, Alexander M.M.F. Appelman, ngeborg Van Der Tweel, D. William Erkelens, and Timon W. Van HaeftenFrom:Diabetes Care (Vol. 25, Issue 1) Peer-Reviewed

  Jan. 20023,908 words Article Edith W.M.T. Ter Braak (1) Alexander M.M.F. Appelman (1) ngeborg Van DerTweel (2) D. William Erkelens (1) Timon W. Van Haeften (1) OBJECTIVE -- The sulfonylurea (SU) glyburide may cause severe and...

• Sulfonylurea-binding sites and ATP-sensitive K+ channels in alpha-TC glucagonoma and beta-TC insulinoma cells

  Authors:Peter Ronner, Franz M. Matshinsky, Hang Tu Le, Andrew J. Epstein, and Carol BeuttgerFrom:Diabetes (Vol. 42, Issue 12) Peer-Reviewed

  Dec. 19937,982 words Article [alpha]-Cells secrete glucagon in a fuel-dependent fashion. We tested the hypothesis that [alpha]-cells contain sulfonylurea- and ATP-sensitive [K.sup.+] channels. We studied two clonal lines of [alpha]-TC cells (simian...

• Sulfonylureas may elevate risk in MI survivors

  Author:Bruce JancinFrom:Family Practice News (Vol. 39, Issue 17)

  Oct. 1, 2009322 words Brief article, Repor... 1360LBARCELONA -- Four widely prescribed oral sulfonylurea drugs are associated with significantly increased risk of all-cause mortality compared with metformin in type 2 diabetic patients having a history of MI, according...

• PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells

  Authors:Lena Eliasson, Erik Renstrom, Carina Ammala, Per-Olaf Berggren, Alejandro M. Bertorello, Krister Bokvist, et al.From:Science (Vol. 271, Issue 5250) Peer-Reviewed

  Feb. 9, 19962,139 words Article Hypoglycemic sulfonylureas represent a group of clinically useful antidiabetic compounds that stimulate insulin secretion from pancreatic p cells. The molecular mechanisms involved are not fully understood but are...

• Sulfonylureas rapidly cross phospholipid bilayer membranes by a free-diffusion mechanism

  Authors:Frits Kamp, Nadeem Kizilbash, Barbara E. Corkey, Per-Olof Berggren, and James A. HamiltonFrom:Diabetes (Vol. 52, Issue 10) Peer-Reviewed

  Oct. 20033,904 words Article Because sulfonylureas directly activate the exocytotic machinery, we were interested in the extent to which these compounds penetrate the [beta]-cell plasma membrane and the underlying molecular mechanism(s). We now...

• Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice

  Authors:Dana M. Niedowicz, Sabire Ozcan, and Peter T. NelsonFrom:Journal of Diabetes Research (Vol. 2018) Peer-Reviewed

  Annual 20187,366 words Report 1390LSulfonylureas are a class of antidiabetes medications prescribed to millions of individuals worldwide. Rodents have been used extensively to study sulfonylureas in the laboratory. Here, we report the results of studies...

• Glucose, sulfonylureas, and neurotransmitter release: role of ATP-sensitive K+ channels

  Authors:Salvatore Amoroso, Heidy Schmid-Antomarchi, Michel Fosset, and Michel LazdunskiFrom:Science (Vol. 247, Issue 4944) Peer-Reviewed

  Feb. 16, 19901,815 words Article Glucose, Sulfonylureas, and Neurotransmitter Release: Role of ATP-Sensitive [K.sup.+] Channels ATP-DEPENDENT POTASSIUM CHANNELS are critical for insulin secretion from pancreatic [beta]-cells [1-3]. They are inhibited...

• When less is more

  Author:Alan J. GarberFrom:Clinical Diabetes (Vol. 12, Issue 3) Peer-Reviewed

  May-June 1994567 words Editorial The results of the Diabetes Control and Complications Trial (DCCT) showed that the incidence of microvascular complications in patients with insulin-dependent diabetes mellitus (IDDM) is directly proportional to the...

• A mutation in the TMD0-L0 region of sulfonylurea receptor-1 (L225P) causes permanent neonatal diabetes mellitus (PNDM)

  Authors:Ricard Masia, Diva D. De Leon, Courtney MacMullen, Heather McKnight, Charles A. Stanley, and Colin G. NicholsFrom:Diabetes (Vol. 56, Issue 5) Peer-Reviewed

  May 20073,232 words Clinical report 1470LOBJECTIVE--We sought to examine the molecular mechanisms underlying permanenent neonatal diabetes mellitus (PNDM) in a patient with a heterozygous de novo L225P mutation in the L0 region of the sulfonylurea receptor...

• Unintentional sulfonylurea toxicity due to a drug-drug interaction: a case report

  Authors:Keith Gunaratne, Emily Austin, and Peter E. WuFrom:BMC Research Notes (Vol. 11, Issue 1) Peer-Reviewed

  May 21, 20181,663 words Case study 1380LBackground Sulfonylureas are widely used for type 2 diabetes mellitus, but these medications carry a risk of hypoglycemia. Drug-drug interactions that inhibit sulfonylurea metabolism and thus increase systemic...

• Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes

  Author:Vivian FonsecaFrom:Diabetes Care (Vol. 28, Issue 8) Peer-Reviewed

  Aug. 2005290 words Brief article Johnson JA, Simpson SH, Toth EL, Majumdar SR: Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22:497-502, 2005 Findings. This retrospective...

• Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis

  Authors:Dan Qian, Tiantian Zhang, Xiangping Tan, Peiying Zheng, Zhuoru Liang, Jingmei Xie, et al.From:PLoS ONE (Vol. 13, Issue 8) Peer-Reviewed

  Aug. 27, 20186,147 words Report 1330LAims This study aimed to investigate the efficacy and safety of dual therapy comprising sulfonylurea (SU) plus antidiabetic drugs for the treatment of type 2 diabetes mellitus (T2DM). Methods We searched the...

• Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3

  Authors:Tiinamaija Tuomi, Elina H. Honkanen, Bo Isomaa, Leeana Sarelin, and Leif C. GroopFrom:Diabetes Care (Vol. 29, Issue 2) Peer-Reviewed

  Feb. 20063,644 words Article OBJECTIVE--To study the effect of the short-acting insulin secretagogue nateglinide in patients with maturity-onset diabetes of the young type 3 (MODY3), which is characterized by a defective insulin response to glucose...

• A down side to some diabetes pills?

  Author:Terri D'ArrigoFrom:Diabetes Forecast (Vol. 59, Issue 6)

  June 2006465 words Drug overview 1500LType 2 Older type 2 pills in a class of drugs called sulfonylureas may cause heart trouble, say researchers at the University of Alberta in Edmonton. Sulfonylureas (SUs) have long been the subject of controversy....

• Closet hypoglycemia

  Authors:Irving Robinson, Robert L. Deamer, and John G. PrichardFrom:Journal of Family Practice (Vol. 38, Issue 1) Peer-Reviewed

  Jan. 1994775 words Article An elderly nondiabetic woman was found stuporous and unresponsive at home. In the emergency department, testing revealed that she had a serum glucose of 40 mg/dL (2.2 mmol/L). No underlying metabolic cause could be...

• Ketone body metabolism in NIDDM: effect of sulfonylurea treatment

  Authors:Angelo Avogaro, Anna Valerio, Luigi Gnudi, Alberto Maran, Mario Zolli, Elena Duner, et al.From:Diabetes (Vol. 41, Issue 8) Peer-Reviewed

  Aug. 19924,039 words Article We assessed the metabolism of the two KBs, AcAc and 3-BOH; the relationships between ketogenesis and FFA inflow rate; and the effect of chronic sulfonylurea treatment in mild NIDDM patients (plasma glucose < 10 mM). We...

• The management of non-insulin-dependent diabetes mellitus in the elderly

  Author:Gary RuoffFrom:Journal of Family Practice (Vol. 36, Issue 3) Peer-Reviewed

  Mar. 19934,488 words Article More than 8 million Americans are afflicted with non-insulin-dependent diabetes mellitus (NIDDM), a complex disease process characterized by insulin resistance and impaired insulin secretion. Diet and exercise continue...

• Sulfonylureas and Heart Disease in Diabetes Management

  Author:N. Wilson RodgerFrom:Diabetes Spectrum (Vol. 12, Issue 2) Peer-Reviewed

  Spring 19992,580 words Article N. Wilson Rodger, MD, FRCPC, CDE, is a professor of medicine and medical director of the Lawson Diabetes Centre at the University of Western Ontario, London, Canada. In Brief The sulfonylureas constitute a class...